title: Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) study.
abstract: BACKGROUND
  We compared the combination plus Carboplatin plus paclitaxel, which is considered the treatment of choice for initial chemotherapy of advanced ovarian cancer (AOC) with a regimen combining alternating carboplatin and cisplatin plus paclitaxel. The two platinum derivatives have been previously combined as they are not totally cross-resistant and as they share no overlapping toxicities.
  
  
  METHODS
  Patients with AOC, after the initial cytoreductive surgery were randomized to either 6 courses of paclitaxel at 175 mg/m2 as 3 h infusion plus Carboplatin at 7 AUC (Arm A) or Paclitaxel at the same dose plus Carboplatin again at 7 AUC for cycles 1,3,5, while for cycles 2,4,6 Cisplatin at 75 mg/m2 substituted for Carboplatin (Arm B).
  
  
  RESULTS
  247 patients are analyzed. Significant differences were not found, both in terms of PFS (38 vs 39 months, p=0.95) and overall survival (40.6 vs 38.6 months, p=0.79). There was not also difference in 5-year survival rate (35% vs 39%) or 5-year PFS rate (23% vs 28%). Age >60, PS 2, stage IV disease and presence of residual disease were adversely related to the overall survival.
  
  
  CONCLUSIONS
  Both regimens are well tolerated and effective. Alternating cisplatin with carboplatin does not improve the results compared with the standard combination.
authors.affiliation: Agii Anargiri Cancer Hospital, Athens, Greece. hecogaga@otenet.gr
authors.forename: G
authors.initials: G
authors.lastname: Aravantinos
authors.forename: G
authors.initials: G
authors.lastname: Fountzilas
authors.forename: P
authors.initials: P
authors.lastname: Kosmidis
authors.forename: M A
authors.initials: MA
authors.lastname: Dimopoulos
authors.forename: G P
authors.initials: GP
authors.lastname: Stathopoulos
authors.forename: N
authors.initials: N
authors.lastname: Pavlidis
authors.forename: D
authors.initials: D
authors.lastname: Bafaloukos
authors.forename: C
authors.initials: C
authors.lastname: Papadimitriou
authors.forename: S
authors.initials: S
authors.lastname: Karpathios
authors.forename: V
authors.initials: V
authors.lastname: Georgoulias
authors.forename: P
authors.initials: P
authors.lastname: Papakostas
authors.forename: H P
authors.initials: HP
authors.lastname: Kalofonos
authors.forename: E
authors.initials: E
authors.lastname: Grimani
authors.forename: D V
authors.initials: DV
authors.lastname: Skarlos
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage; D010349:Patient Compliance; D011446:Prospective Studies; D016019:Survival Analysis
chemical_list: D016190:Carboplatin; D017239:Paclitaxel; D002945:Cisplatin